Nevirapine Medical Valley

Nevirapine, the active ingredient in Nevirapine Medical Valley, is a non‑nucleoside reverse transcriptase inhibitor presented as an oral tablet for oral use. Approved in the European Union, it is incorporated into combination regimens for the treatment of HIV‑1 infection in adults and adolescents.

GNH USA supplies Nevirapine Medical Valley as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on reliable quality and regulatory compliance for antiretroviral medicines, and ensuring timely delivery across global markets.

Nevirapine is an NNRTI used in antiretroviral therapy for HIV‑1 infection.

- HIV‑1 infection (adults): reduces plasma HIV RNA levels as part of combination therapy. - HIV‑1 infection (adolescents): helps achieve viral suppression when used with other agents. - HIV‑1 infection (treatment‑experienced patients): provides an alternative NNRTI option in salvage regimens.

Nevirapine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Rash: mild to moderate skin eruptions, often early in therapy. - Nausea: transient gastrointestinal discomfort. - Fatigue: general feeling of tiredness. - Headache: mild to moderate intensity. - Elevated liver enzymes: mild transaminase increase.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions requiring immediate discontinuation. - Hepatotoxicity: significant liver injury, potentially leading to jaundice or hepatic failure. - Hypersensitivity reactions: including fever, eosinophilia, and systemic symptoms.

Before initiating therapy, clinicians should consider several safety measures.

- Liver function monitoring: assess baseline transaminases and repeat regularly during therapy. - Skin reactions: discontinue immediately if rash progresses to SJS/TEN. - Pregnancy: use only if benefits outweigh potential risks; data are limited. - Drug interactions: review concomitant medications for CYP3A4 inducers or inhibitors. - Adherence: maintain consistent dosing to avoid resistance development. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Nevirapine interacts with several agents that can alter its plasma levels or increase toxicity.

Major Interactions (Avoid): - Ritonavir‑boosted protease inhibitors: may raise nevirapine concentrations and heighten hepatotoxic risk. - St. John's wort (hypericum perforatum): induces CYP3A4, reducing nevirapine exposure. - Efavirenz: co‑administration can increase liver toxicity.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): may increase nevirapine levels. - Macrolide antibiotics (e.g., erythromycin): can affect metabolism. - Oral contraceptives: nevirapine may lower efficacy; advise additional contraceptive measures.